MiNK Therapeutics, Inc.

NASDAQ:INKT

Biotechnology

Healthcare
$10.22 -2.87%

-$0.35 today

Market cap
$52.17M
Beta
0.47
P/E (TTM)
-4.6
EPS (TTM)
-$2.60
52W Low $6.80High $76.00

Volume 0.01M

Average 0.05M

INKT Short-term Debt

Borrowings and the current portion of long-term debt due within one year.

MiNK Therapeutics, Inc.NASDAQ: INKT

Short-term Debt · Q1 FY2026 · quarter ended Mar 2026

Short-term debt remains negative

Q1 FY2026 short-term debt was $0, compared with $5.12M a year earlier.

Context

  • Short-term debt amounted to 0.0% of total assets at the end of Q1 FY2026, down 119.9 pp from a year earlier.
  • Short-term debt increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether short-term debt keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$5.18M— YoY
Year agoMar 2025
$5.12M-100.0% since
Short-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Short-term Debt history

USD · from the balance sheet

Latest · FY2025
5.18M USD
Year-over-year change
—

Short-term Debt vs competitors

How INKT compares with its peers on the latest reported figures

  • INKT's Mar 2026 short-term debt of $0 is the 6th highest of the 9 companies compared; the peer median is $270.64K.
  • Its year-over-year change of -100.0% is the 5th highest of 7, against a peer median of -43.7%.
  • Short-term debt amounts to 0.0% of total assets for INKT, versus a peer median of 0.6%.
INKT Competitors Peer median
Short-term Debt for INKT and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
OSTXOS Therapies IncorporatedMar 2026$1.34B ——18398.4%
OTLKOutlook Therapeutics, Inc.Mar 2026$15.85M +32.0%+40.0%72.4%
SPRBSpruce Biosciences, Inc.Mar 2026$1M -25.7%—1.8%
EQEquillium, Inc.Mar 2026$441K +202.1%-60.1%0.7%
GANXGain Therapeutics, Inc.Mar 2026$100.28K -61.7%-2.3%0.5%
INKTMiNK Therapeutics, Inc.Mar 2026$0 -100.0%—0.0%
NRXPNRx Pharmaceuticals, Inc.Mar 2026$0 -100.0%—0.0%
VTVTvTv Therapeutics Inc.Mar 2026$0 ——0.0%
HOWLWerewolf Therapeutics, Inc.Jun 2026$0 -100.0%—0.0%
Peer median (excluding INKT) $270.64K-43.7%-2.3%0.6%

Competitors are the stored peer set for INKT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents38.89M19.64M3.37M4.58M13.36M
Short-term Investments00000
Net Receivables23K0000
Inventory00000
Other Current Assets721.32K470.3K177.96K164.24K211.2K
Total Current Assets39.63M20.4M3.6M4.99M13.85M
Property, Plant & Equipment (Net)606.6K1.07M953.98K732.93K390.87K
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets00000
Total Non-current Assets606.6K1.07M953.98K732.93K390.87K
Total Assets40.24M21.47M4.55M5.72M14.24M
Account Payables3M5.82M3.91M2.73M3.43M
Short-term Debt00005.18M
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities5.76M5.21M5.66M3.51M2.85M
Total Current Liabilities16.47M12.68M11.4M6.96M13.03M
Long-term Debt0004.92M0
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities09.19M11.21M13.42M15.44M
Total Non-current Liabilities09.19M11.21M18.35M15.44M
Total Liabilities16.47M21.87M22.61M25.31M28.47M
Common Stock3353393464048
Retained Earnings(82.95M)(110.94M)(133.4M)(144.18M)(156.68M)
Accumulated OCI(625.27K)(292.47K)(430.95K)(631.58K)(718.92K)
Other Stockholders Equity0900000
Minority Interest00000
Total Equity23.78M(401.3K)(18.06M)(19.59M)(14.23M)
Total Debt0004.92M5.18M
Net Debt(38.89M)(19.64M)(3.37M)347.57K(8.18M)

MiNK Therapeutics, Inc.

NASDAQ:INKT

Intrinsic Alpha fair value

Locked

Current Price

$10.22

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.